Round Two: BioMarin Resubmits Hemophilia A Gene Therapy Roctavian In US
Conditional Approval Granted In EU In August
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.
